{
  "denotations": [
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 73,
        "end": 79
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 133,
        "end": 140
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 157,
        "end": 166
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 234,
        "end": 241
      }
    },
    {
      "id": "T9",
      "obj": "Disease",
      "span": {
        "begin": 259,
        "end": 267
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 339,
        "end": 348
      }
    },
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 26,
        "end": 57
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 36,
        "end": 43
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 48,
        "end": 57
      }
    },
    {
      "id": "T13",
      "obj": "Chemical",
      "span": {
        "begin": 286,
        "end": 293
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22030088_4",
  "text": "We examined the effect of combining aspirin and celecoxib in relation to UGT1A6 T181A and R184S variants among 1,647 patients in the Adenoma Prevention with Celecoxib ( APC ) trial who were stratified according to the use of low-dose aspirin after removal of adenomas and randomized to placebo , 200-mg twice daily , or 400-mg twice daily celecoxib for 3 years ."
}
